指南与共识呼吸衰竭与机械通气心脑血管急症

急性肺栓塞患者家庭治疗标准(EARTH规则):国际德尔菲共识研究

Criteria for home treatment of patients with acute pulmonary embolism (the Emergency Advisory and Research international board on Thrombosis and Hemostasis EARTH - rule): an international Delphi consensus study.
指南 / 共识 · J Thromb Haemost · 2025-02-09
一句话结论EARTH共识确立低危急性肺栓塞家庭治疗的分诊规则:6项不良事件复合终点、出院后7天安全窗、可接受发生率上限2.0%,14项临床禁忌证分4类,另加3项可选生物学或影像学标准。

该国际德尔菲共识旨在明确低危急性肺栓塞患者家庭治疗中哪些不良事件使家庭出院不适当,以及其时间窗和临床标准。经系统文献回顾后,国际专家小组进行3轮德尔菲调查,共识需75%同意。55名受邀专家中38名来自13个国家参与(69%)。共识确定6项不良事件复合终点、出院后7天时间窗和最高可接受发生率2.0%,并定义分诊规则:14项临床标准作为家庭治疗禁忌证,分为血流动力学(3项)、呼吸(1项)、出血(7项)和医学-社会(3项)4类;扩展规则另加3项可选的生物学或影像学标准以进一步细化风险评估。作者指出,在临床实践实施前需前瞻性研究验证EARTH规则。

要点

  • 共识确定家庭治疗安全评估采用6项不良事件复合终点,时间窗为出院后7天,最高可接受发生率2.0%。
  • 分诊规则含14项临床标准作为家庭治疗禁忌证:血流动力学3项、呼吸1项、出血7项、医学-社会3项。
  • 扩展规则另加3项可选的生物学或影像学标准,用于进一步细化风险评估。
  • 38名来自13个国家的专家参与3轮德尔菲调查(受邀55名,参与率69%),共识阈值75%同意。
  • 作者指出,EARTH规则在临床实践实施前需前瞻性研究验证。

适用人群与场景

  • 低危急性肺栓塞患者,评估是否适合家庭治疗。

诊断标准与关键阈值

  • 共识定义6项不良事件作为复合终点,评估时间窗为出院后7天,最高可接受发生率为2.0%。
  • 分诊规则以14项临床标准作为家庭治疗禁忌证,分为4类:血流动力学3项、呼吸1项、出血7项、医学-社会3项。
  • 扩展规则在14项临床标准基础上增加3项可选的生物学或影像学标准,以进一步细化风险评估。

研究设计与关键结果

  • 采用德尔菲共识方法:经系统文献回顾后,国际专家小组进行3轮德尔菲调查,专家用Likert量表评估每项提案,共识需75%同意,未达成共识的项目在后续轮次重新评估直至达成一致。
  • 55名受邀专家中38名来自13个国家参与(69%)。
  • 共识达成6项不良事件复合终点、出院后7天时间窗和最高可接受发生率2.0%。
  • 共识确定14项临床标准作为家庭治疗禁忌证(血流动力学3项、呼吸1项、出血7项、医学-社会3项),并制定增加3项可选生物学或影像学标准的扩展规则。

证据类型、等级与局限

  • 证据类型:国际德尔菲共识研究。
  • 共识阈值:75%同意。
  • 局限:未来需前瞻性研究验证EARTH规则后方可在临床实践中实施(原文指出Future prospective studies are needed to validate the Emergency Advisory and Research international board on Thrombosis and Hemostasis rule before its implementation in clinical practice)。

对床旁实践的改变

  • 作者建立的共识框架定义了低危急性肺栓塞家庭治疗评估的不良结局、出院后7天安全时间窗和可接受风险阈值2.0%。
  • 作者提出的分诊规则以14项临床标准(血流动力学3项、呼吸1项、出血7项、医学-社会3项)作为家庭治疗禁忌证,扩展规则另加3项可选生物学或影像学标准。
  • 作者指出,EARTH规则在临床实践实施前需前瞻性研究验证。

指南或共识出处

  • 指南名称:急性肺栓塞患者家庭治疗标准(EARTH规则);发布机构:Emergency Advisory and Research international board on Thrombosis and Hemostasis;期刊:J Thromb Haemost;年份:原文未写明。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The safety of home treatment for patients with low-risk acute pulmonary embolism (PE) has been confirmed in several studies; however, these studies have used varying triaging criteria and outcomes, leading to inconsistencies in defining safe discharge parameters. This study aimed to identify adverse outcomes that make home discharge inappropriate, as well as their timeframe and clinical criteria, indicating high risk for such events. Following a systematic literature review, an international expert panel participated in 3 Delphi survey rounds. Experts evaluated each proposal using a Likert scale, and consensus required 75% agreement. Items without consensus were reassessed in subsequent rounds until agreement was achieved. Of the 55 invited experts, 38 from 13 countries participated (69%). Consensus was reached on 6 adverse events for a composite outcome, with a 7-day postdischarge timeframe and a maximum acceptable incidence of 2.0%. The panel defined a triaging rule with 14 clinical criteria as contraindications for home treatment, grouped into 4 categories: hemodynamic (3), respiratory (1), hemorrhagic (7), and medico-social (3). An extended rule, adding 3 optional biological or imaging criteria, was developed to further refine risk assessment. The expert panel established a consensus-based triaging rule for the home treatment of PE patients. This framework defines adverse outcomes, a 7-day safety timeframe, and an acceptable risk threshold for assessing patient safety. Future prospective studies are needed to validate the Emergency Advisory and Research international board on Thrombosis and Hemostasis rule before its implementation in clinical practice.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

参考来源

  1. Servent M, Casey SD, Stubblefield WB, et al. Criteria for home treatment of patients with acute pulmonary embolism (the Emergency Advisory and Research international board on Thrombosis and Hemostasis EARTH - rule): an international Delphi consensus study. J Thromb Haemost. 2025. PMID: 39933653. doi:10.1016/j.jtha.2025.01.016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。